Skip to main content
OpenTrials

Clinical trial condition

Relapsed Hematologic Malignancy

Explore clinical trials studying Relapsed Hematologic Malignancy. Study availability and eligibility vary by location and protocol.

8 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Relapsed Hematologic Malignancy trial results

Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078

Conditions
Disease Attributes, Hematologic Diseases, Hematologic Neoplasms, +17 more
Locations
  • St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Providence St. John's Health Center Santa Monica, California, United States
View all 45 locations
View Trial Details
Recruiting

International Leukemia Target Board

NCT05270096

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hemic and Lymphatic Diseases, +6 more
Locations
  • UH Gent Ghent, Belgium
  • Righospitalet Copenhagen, Denmark
  • Semmelweis Budapest, Hungary
  • Princess Máxima Center for Pediatric Oncology Utrecht, Netherlands
View Trial Details
Recruiting

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

NCT06615193

Conditions
Advanced Solid Tumors, Hematologic Diseases, Hematologic Neoplasms, +11 more
Locations
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
  • The Second Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
View Trial Details

Related conditions